Anthera Pharmaceuticals Stock Performance
| ANTH Stock | USD 0.0001 0.00 0.00% |
Anthera Pharmaceuticals holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -3.18, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Anthera Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Anthera Pharmaceuticals is expected to outperform it. Use Anthera Pharmaceuticals treynor ratio and rate of daily change , to analyze future returns on Anthera Pharmaceuticals.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Anthera Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Anthera Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 20.8 M | |
| Total Cashflows From Investing Activities | -919.9 K | |
| Free Cash Flow | -36.9 M |
Anthera |
Anthera Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.01 in Anthera Pharmaceuticals on September 30, 2025 and sell it today you would earn a total of 0.00 from holding Anthera Pharmaceuticals or generate 0.0% return on investment over 90 days. Anthera Pharmaceuticals is currently generating 12.8571% in daily expected returns and assumes 114.1367% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Anthera, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Anthera Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Anthera Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Anthera Pharmaceuticals, and traders can use it to determine the average amount a Anthera Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1126
| Best Portfolio | Best Equity | ANTH | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Anthera Pharmaceuticals is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Anthera Pharmaceuticals by adding it to a well-diversified portfolio.
Anthera Pharmaceuticals Fundamentals Growth
Anthera Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Anthera Pharmaceuticals, and Anthera Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Anthera Pink Sheet performance.
| Return On Equity | -5.69 | |||
| Return On Asset | -1.42 | |||
| Current Valuation | (7.47 M) | |||
| Shares Outstanding | 26.18 M | |||
| Price To Earning | (0.20) X | |||
| Price To Book | 0.11 X | |||
| EBITDA | (26.59 M) | |||
| Cash And Equivalents | 8.09 M | |||
| Cash Per Share | 0.31 X | |||
| Debt To Equity | 1.61 % | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (36.9 M) | |||
| Earnings Per Share | (1.76) X | |||
| Total Asset | 3.67 M | |||
| Retained Earnings | (436.8 M) | |||
| Current Asset | 47.86 M | |||
| Current Liabilities | 8.47 M | |||
About Anthera Pharmaceuticals Performance
By evaluating Anthera Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Anthera Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Anthera Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Anthera Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas. Anthera Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 21 people.Things to note about Anthera Pharmaceuticals performance evaluation
Checking the ongoing alerts about Anthera Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Anthera Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Anthera Pharmaceuticals is way too risky over 90 days horizon | |
| Anthera Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Anthera Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (26.87 M) with loss before overhead, payroll, taxes, and interest of (28.49 M). | |
| Anthera Pharmaceuticals currently holds about 8.09 M in cash with (36.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Anthera Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Anthera Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Anthera Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Anthera Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Anthera Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Anthera Pharmaceuticals' pink sheet. These opinions can provide insight into Anthera Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Anthera Pink Sheet analysis
When running Anthera Pharmaceuticals' price analysis, check to measure Anthera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anthera Pharmaceuticals is operating at the current time. Most of Anthera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Anthera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anthera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Anthera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |